B Cell-Dependent TCR Diversification

João, Cristina; Ogle, Brenda M.; Gay-Rabinstein, Carlota; Platt, Jeffrey L.; Cascalho, Marília

doi:10.4049/jimmunol.172.8.4709

Cited by 69 publications

(70 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent report demonstrated that polyclonal immunoglobulin administration is able to increase TCR repertoire diversity in an animal model with a contracted T-cell repertoire. 34 This could represent a possible approach to be tested clinically. The possibility of improving repertoire diversity and function of the T cells that populate the immune system after ASCT will allow better immune function and, possibly, a lower recurrence rate.…”

Section: Discussionmentioning

confidence: 99%

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma

Joao

Porrata

Inwards

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

Autologous stem cell transplantation (ASCT) is an effective treatment strategy for mantle-cell lymphoma (MCL) demonstrating significantly prolonged progression-free survival (PFS) when compared to interferon-a maintenance therapy of patients in first remission. The study of absolute lymphocyte count at day 15 (ALC-15) after ASCT as a prognostic factor in non-Hodgkin lymphoma (NHL) included different lymphoma subtypes. The relationship of ALC-15 after ASCT in MCL has not been specifically addressed. We evaluated the impact of ALC-15 recovery on survival of MCL patients undergoing ASCT. We studied 42 consecutive MCL patients who underwent ASCT at the Mayo Clinic in Rochester from 1993 to 2005. ALC-15 threshold was set at 500 cells/ll. The median follow-up after ASCT was 25 months (range, 2-106 months). The median overall survival (OS) and PFS times were significantly better for the 24 patients who achieved an ALC-15 X500 cells/ll compared with 18 patients with ALC-15 o500 cells/ll (not reached vs 30 months, Po0.01 and not reached vs 16 months, Po0.0006, respectively). Multivariate analysis demonstrated ALC-15 to be an independent prognostic factor for OS and PFS. The ALC-15 X500 cells/ll is associated with a significantly improved clinical outcome following ASCT in MCL.

show abstract

Section: Discussionmentioning

confidence: 99%

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma

Joao

Porrata

Inwards

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Our data support this hypothesis and underline the presence of maternal autoimmune imprinting for T1D in the NOD mouse. In a recent report it has been shown that T cell restriction and positive selection are affected by B cells and Ig (34). Thus, in autoimmune diseases a similar role might be attributed to B cells.…”

Section: Maternal Autoimmune Imprinting Predisposes Offspring To T1dmentioning

confidence: 99%

Early and Quantal (by Litter) Expression of Insulin Autoantibodies in the Nonobese Diabetic Mice Predict Early Diabetes Onset

Melanitou

Devendra

Liu

et al. 2004

The Journal of Immunology

View full text Add to dashboard Cite

International audienceAiming to study the early stages of type 1 diabetes phenotype, before insulitis appears, we measured insulin autoantibodies (IAA) between 3 and 5 wk of age in the NOD mouse (early-IAA (E-IAA)). We report that IAA are found as early as at 3 wk of age, at weaning, and their expression is a quantal phenotype. Maternal autoantibody status influences this early phenotype, because animals of litters issued from IAA-positive ante partum mothers develop E-IAA with a significantly higher incidence than animals issued from IAA-negative mothers. These E-IAA represent synthesized rather than transplacental autoantibodies, as evidenced by higher levels in many offspring compared with maternal IAA, and negative as well as positive offspring in the same litters and it correlates with early diabetes onset, defining the first autoimmune window in diabetes pathogenesis. Therefore, autoimmune processes leading to type 1 diabetes initiate early in life, are influenced by maternal autoantibody status, and can be revealed by the presence of IAA. Our data suggest that the mechanisms responsible for the breakdown of self-tolerance are subjected not only to genetic predisposition, but also to the physiological status of the mother. Pathological progression to autoimmunity is marked by the presence of immunological windows relating early steps with final disease onset

show abstract

“…Furthermore, costimulatory molecules (such as CD80, CD86, and OX40L) expressed on the surface of B cells are required for optimal T cell activation [10,11]. The positive regulatory roles of B cells extend to multiple immune system components; the absence of B cells during mouse development results in significant quantitative and qualitative abnormalities within the immune system, including a remarkable decrease in thymocyte numbers and diversity [12], significant defects within spleen dendritic cell and T cell compartments [13-15], absence of Peyer's patch organogenesis and follicular dendritic cell networks [16,17], and absence of marginal zone and metallophilic macrophages with decreased chemokine expression [15,17]. B cells also positively regulate lymphoid tissue organization [18,19].…”

Section: Introductionmentioning

confidence: 99%

IL-10-producing regulatory B cells (B10 cells) in autoimmune disease

2013

View full text Add to dashboard Cite

B cell abnormalities contribute to the development and progress of autoimmune disease. Traditionally, the role of B cells in autoimmune disease was thought to be predominantly limited to the production of autoantibodies. Nevertheless, in addition to autoantibody production, B cells have other functions potentially relevant to autoimmunity. Such functions include antigen presentation to and activation of T cells, expression of co-stimulatory molecules and cytokine production. Recently, the ability of B cells to negatively regulate cellular immune responses and inflammation has been described and the concept of regulatory B cells has emerged. A variety of cytokines produced by regulatory B cell subsets have been reported, with IL-10 being the most studied. In this review, this specific IL-10-producing subset of regulatory B cells has been labeled B10 cells to highlight that the regulatory function of these rare B cells is mediated by IL-10, and to distinguish them from other B cell subsets that regulate immune responses through different mechanisms. B10 cells are a functionally defined subset currently identified only by their competency to produce and secrete IL-10 following appropriate stimulation. Although B10 cells share surface markers with other previously defined B cell subsets, currently there is no cell surface or intracellular phenotypic marker or set of markers unique to B10 cells. The recent discovery of an effective way to expand B10 cells ex vivo opens new horizons in the potential therapeutic applications of this rare B cell subset. This review highlights the current knowledge on B10 cells and discusses their potential as novel therapeutic agents in autoimmunity.

show abstract

B Cell-Dependent TCR Diversification

Cited by 69 publications

References 43 publications

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma

Early and Quantal (by Litter) Expression of Insulin Autoantibodies in the Nonobese Diabetic Mice Predict Early Diabetes Onset

IL-10-producing regulatory B cells (B10 cells) in autoimmune disease

Contact Info

Product

Resources

About